Maze Therapeutics R&D president and chief medical officer Harold Bernstein said: “We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase II clinical trial with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback